Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 5
1979 4
1980 4
1981 1
1983 3
1984 4
1987 1
1988 6
1989 1
1990 3
1991 4
1992 1
1993 2
1994 1
1995 3
1996 1
1997 3
1998 1
1999 3
2000 2
2001 1
2002 3
2003 3
2004 5
2005 4
2006 13
2007 11
2008 12
2009 9
2010 5
2011 11
2012 6
2013 11
2014 11
2015 6
2016 12
2017 10
2018 18
2019 11
2020 15
2021 8
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

231 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Zinman B, et al. Among authors: fitchett d. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. N Engl J Med. 2015. PMID: 26378978 Free article. Clinical Trial.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Marso SP, et al. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. N Engl J Med. 2016. PMID: 27633186 Free article. Clinical Trial.
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Wanner C, et al. Among authors: fitchett d. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14. N Engl J Med. 2016. PMID: 27299675 Free article. Clinical Trial.
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, Zuo F, Quan A, Farkouh ME, Fitchett DH, Goodman SG, Goldenberg RM, Al-Omran M, Gilbert RE, Bhatt DL, Leiter LA, Jüni P, Zinman B, Connelly KA. Verma S, et al. Among authors: fitchett dh. Circulation. 2019 Nov 19;140(21):1693-1702. doi: 10.1161/CIRCULATIONAHA.119.042375. Epub 2019 Aug 22. Circulation. 2019. PMID: 31434508 Clinical Trial.
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators. Wanner C, et al. Among authors: fitchett d. Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13. Circulation. 2018. PMID: 28904068 Clinical Trial.
To Risk Stratify or Not for Statin Therapy.
Fitchett D. Fitchett D. Can J Cardiol. 2019 May;35(5):550-551. doi: 10.1016/j.cjca.2019.01.009. Epub 2019 Jan 25. Can J Cardiol. 2019. PMID: 31030856 No abstract available.
231 results